[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malaria-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malaria-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,96,126,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100635079","phase-1-safety-and-pk-of-mmv371-lai-in-healthy-adults-and-adolescents-in-rwanda-100635079",false,"NCT07548021","Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda","A Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 Long-Acting Injection in Healthy Adults and Adolescents in Rwanda","Inclusion Criteria:\n\n1. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For adolescents, written assent and parental\u002Flegal authorized representative (LAR) consent must be obtained, in accordance with local regulations.\n2. Able to provide proof of identity to the satisfaction of the Investigator or delegate completing the enrolment process\n3. Able and willing to communicate effectively and comply with all study procedures for the duration of the study (including IM injections, safety assessments, blood sampling, malaria monitoring, follow-up visits)\n4. Living within local jurisdiction of trial site(s) and available for the duration of the trial Demographics and Contraception\n5. Male or female participants aged 12 to 50 years inclusive at the time of signing informed consent\u002Fassent.\n6. WOCBP must be non-pregnant and non-lactating, confirmed by a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test at admission, prior to IMP administration. WOCBP must agree to use, at minimum, acceptable contraception methods, as defined by the Clinical Trials Coordination Group (CTCG) guidance, from 21 days prior to study Day 1 through the End-of Study visit (Week 24) (Clinical Trials Coordination Group (CTCG), 2024).\n7. Post-menopausal participants must have menopause confirmed at screening, defined as a follicle-stimulating hormone (FSH) level ≥ 25.8 mIU\u002FmL Baseline Characteristics\n8. Healthy volunteers, as determined by:\n\n   physical examination Vital signs 12 lead ECG absence of malaria symptoms at baseline (note: a positive blood smear without malaria symptoms at baseline is not exclusionary) Hematology, biochemistry or urinalysis results at screening or at the admission visit (Day -1) that are within the standard clinically acceptable laboratory ranges defined for this study (See section 10.7 Appendix 7)\n9. For adults (18-50 years): Body Weight ≥45 kg at screening\n10. For adolescents (12-17 years): body weight ≥35 kg at screening Participant-reported outcomes (PROs)\n11. Able to understand and complete participant-reported outcome assessments (e.g., injection-site reaction diary and injection acceptability assessments), either independently or with assistance, in a language and format approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Medical Conditions\n\n  1. Positive malaria blood smear microscopy at the Admission visit (Day -1).\n  2. Acute febrile illness within 96 hours prior to enrolment or within 96h prior to Day 1.\n  3. Serious adverse reaction or clinically significant hypersensitivity to drugs or formulation excipients used in the study: artemether-lumefantrine (Coartem® or generic formulations) and atovaquone (Wellvone®\u002FMepron® and\u002For Malarone® or their generics).\n  4. Any history of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrolment that, in the opinion of the Investigator, has a reasonable risk of recurrence during the trial.\n  5. Any current uncontrolled medical or psychiatric condition, or substance abuse problems that, in the opinion of the Investigator, would make it unlikely for the participant to comply with the protocol, may interfere with study assessments, or could jeopardize the safety of the participant.\n  6. Evidence of clinically significant neurologic, cardiac, gastro-intestinal, dermatologic, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, haematological, oncologic, or renal disease, as determined by medical history, physical examination, and\u002For laboratory evaluations, including urinalysis.\n  7. History of a bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or a history of significant bruising with blood draws.\n  8. Known or documented sickle cell disease by history. Note: known sickle cell trait is not exclusionary.\n  9. Presence of sinus node dysfunction; clinically significant PR interval prolongation (\\>220 msec); intermittent second- or third-degree atrioventricular block; complete bundle branch block; sustained cardiac arrhythmias including, but not limited to, atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia except isolated extrasystoles; abnormal T wave morphology that may interfere with QT\u002FQTc assessment; or QTcF \\>450 msec (adults and adolescents).\n\n     Physical Examination\n  10. Participants who do not have adequate venous access for multiple venipunctures or cannulation, as assessed by the Investigator or delegate at screening.\n  11. Participants with tattoos, scars or other clinically significant dermatological lesions or conditions overlying the deltoid, gluteal, or vastus lateralis region that, in the opinion of the Investigator, may interfere with injection site assessments.\n\n      Diagnostic Assessments\n  12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab). or human immunodeficiency virus (HIV) 1 and 2 antibody results.\n\n      Prior Study Participation\n  13. Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or within fewer than 5 elimination half-lives prior to Day 1 (whichever is longer). Note: Past, current, or planned participation in non-interventional (observational) studies is not exclusionary.\n  14. Participants who are currently enrolled in another interventional clinical trial within 90 days prior to Day 1, or who intend to participate in another interventional clinical trial during their participation in this study.\n  15. Donation of blood or plasma, or loss of more than 400 mL of blood, within 90 days prior to Day 1.\n\n      Prior and Concomitant Medication or Vaccine\n  16. Use of antimalarial chemoprevention or treatment, and\u002For antibiotics with known antimalarial activity (see Section 10.6 Appendix 6), within 6 weeks or fewer than 5 elimination half-lives prior to Screening (whichever is longer).\n  17. Current or recent (within 30 days prior to Day 1) use of rifampin\u002Frifampicin, rifabutin, tetracycline, or indinavir due to potential drug-drug interaction risk with atovaquone.\n  18. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \\>10 mg\u002Fday) or other immunosuppressive drugs within 30 days prior to Day 1.\n  19. Receipt of a live attenuated vaccine within 4 weeks or an inactivated vaccine within 2 weeks prior to Day 1.\n  20. Receipt or planned receipt during the study of any doses of a malaria vaccine (investigational or registered, such as RTS, S\u002FAS01 or R21\u002FMatrix-M) or monoclonal antibodies (mAb) directed against Plasmodium falciparum.\n  21. Receipt of immunoglobulins and\u002For blood products within the past 6 months. Lifestyle Characteristics\n  22. History or medical, occupational, or family problems related to alcohol or illicit drug use within the past 12 months that, in the opinion of the Investigator, may interfere with study participation, compliance, or participant safety.\n\n      Other Exclusion Criteria\n  23. Participants who are, or are immediate family members of, study site staff or Sponsor employees involved in the conduct of the study.\n  24. Any other condition or circumstance that, in the opinion of the Investigator, would make the participant unsuitable for the study or could compromise participant safety or data integrity.",true,"ALL","12 Years","50 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda. MMV371 has been designed as a long acting injection (LAI). Protective efficacy (PE) will be assessed as an exploratory endpoint. Protective efficacy measures if participants are protected from becoming ill with malaria whilst the MMV371 is still present in their body. The study will enroll approximately 80 healthy male and female participants, aged 12 to 50 years. Before starting the study participants will be given a standard approved course of artemether lumifantrine (AL) to clear any malaria infection they have. Once the AL course has been completed the study drug will be given by injection in the muscle of the upper arm, the side of the thigh, or the hip. Three out of four participants will receive MMV371 and 1 in four participants will receive placebo. Placebo is a dummy medicine. All participants have an equal chance of being assigned to receive the injection in the upper arm, outer thigh or hip. Neither the participants nor the researchers treating the participants will know who received MMV371 or placebo until after the study is completed.\n\nKey study features include:\n\n* Study duration for each participant: up to 7 months\n* MMV371 or placebo given: a single intramuscular (IM) injection\n* Visit schedule: Participants will remain in-clinic on Days -1-2 (2 overnight stays), followed by 15 follow-up visits: Day 4, then weekly for 1 month, and subsequently every 2 weeks until the End-of-Study (EoS) visit at Week 24.\n\nThese frequent visits are necessary to monitor safety, the levels of MMV371 in the body, and to perform malaria detection testing until EoS (Week 24).",[28,29,30,31,32,33,34],"Malaria (Plasmodium Falciparum)","Malaria Falciparum","Malaria Infection","Malaria Prophylaxis","Malaria Prevention","Malaria","Malaria Parasitaemia",[36,37,38,39,40,41],"malaria prevention","malaria prophylaxis","malaria falciparum","Malaria infection","Malaria Long-Acting Injectable","Long-Acting Injectable","NOT_YET_RECRUITING","2026-04-17",{"date":45,"type":46},"2026-04-23","ACTUAL",{"date":48,"type":22},"2026-09",{"date":50,"type":22},"2028-03",{"name":52,"class":53},"Medicines for Malaria Venture","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":54},"100595929","phase-4-comparison-of-two-strategies-for-administering-the-r21-matrix-m-vaccine-in-a-context-of-seasonal-malaria-transmission-in-chad-100595929","NCT07038837","Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad","Cluster Randomised Non-inferiority Trial Comparing Malaria Incidence When Implementing R21\u002FMatrix-M Synchronized With Seasonal Malaria Chemoprevention Distribution Versus R21\u002FMatrix-M Given Routinely Through the EPI in Two Health Districts in Chad (CoSAV-R21)","COSAV-R21","Inclusion Criteria:\n\n* • Routine arm\n\n  1. Aged 6 to 11 months at the time of the first R21\u002FMM vaccination (dose 1).\n  2. Residing in a village participating in the study and randomized to the routine arm.\n  3. Oral consent provided by the child's parent\u002Fguardian.\n\n     * Synchronised arm\n\n  \u003C!-- -->\n\n  1. Aged 6 to 59 months at the time of the first R21\u002FMM vaccination (dose 1) during the first 3 rounds of SMC (2025).\n  2. Residing in a village participating in the study and randomized to the synchronized arm.\n  3. Oral consent provided by the child's parent\u002Fguardian.\n\nExclusion Criteria:\n\n* Exclusion criteria for both arms according to Chad national EPI guidelines\n\nMalaria vaccine is not recommended for children with known severe hypersensitivity:\n\n* To a previous dose of a malaria vaccine\n* To a previous dose of hepatitis B vaccine\n* One of the components of the R21\u002FMM vaccine\n\nMild illness - including respiratory tract infections, mild diarrhoea and fever below 38.5° C - is not a contraindication to R21\u002FMM vaccination. Malnutrition and being HIV-seropositive are also not contraindications to R21\u002FMM vaccination.","6 Months","59 Months",{"count":66,"type":22},70000,[68],"PHASE4","This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21\u002FMM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, among children living in areas of high seasonal malaria transmission.\n\nIn this study, a cluster is defined as the catchment area of a primary care health centre. In Chad, each catchment area is known as a 'zone of responsibility' (French: Zone de Responsibilité' \\[ZR\\]).\n\nTwenty-six (26) of the total 27 ZRs in the districts of Moïssala and Dembo will be randomized in a 1:1 ratio to receive a 4-dose (3 primary doses + 1 booster) R21\u002FMM schedule either (1) integrated into the routine EPI vaccination program (the \"Routine\" control arm), or (2) synchronized with an annual seasonal malaria chemoprevention (SMC) campaign (the \"Synchronized\" intervention arm).\n\nMalaria incidence: R21\u002FMM effectiveness will be assessed using the incidence of biologically confirmed clinical malaria (trial primary endpoint). The incidence of clinical malaria will be determined through enhanced surveillance of malaria cases in health centres and hospitals over a 17-month period (August 2025 - December 2026).\n\nCoverage surveys: Cross-sectional surveys (cluster sampling) will be carried out to measure R21\u002FMM vaccine coverage, SMC coverage, coverage of other malaria prevention measures, and coverage of other EPI vaccines.\n\nNested case-control study: A sub-sample of children admitted to Moïssala District Hospital with severe clinical malaria will be offered the opportunity to participate in a nested case-control study designed to estimate the individual protective efficacy of R21\u002FMM against severe malaria.\n\nAditionnaly, the INTEGREVAC ancillary study's objective is to evaluate the cost-effectiveness, acceptability and feasibility of the synchronised vaccination strategy in the context of the ongoing COSAV-R21 trial, to inform policy decisions for the effective deployment of malaria vaccines in SMC implementation areas.\n\nMethodology and planned work:\n\n(i) A qualitative study using in-depth interviews (IDIs) and group discussions with key stakeholders at the national, health facility, and community levels, including caregivers of children eligible for vaccination, in Chad, at several points during the trial. We will explore stakeholders' and beneficiaries' perceptions and experiences of the synchronised SMC vaccination strategy (trial intervention arm) compared to age-based vaccine administration under the routine immunisation programme (trial control arm), as well as considerations for implementing these strategies. Interviews with healthcare providers, including those administering R21 and SMC, and community members will assess the feasibility of implementing the integrated vaccination strategy via SMC.\n\n(ii) An economic evaluation including a cost-effectiveness analysis and a nested equity analysis will be conducted. The economic evaluation will include a cost analysis to carefully identify and measure the additional costs associated with adding malaria vaccination to the EPI delivery platform and, separately, to the SMC delivery channel. Analysis of key cost drivers will enable us to identify potential efficiency savings, provide evidence for country funding requests (e.g., to GAVI and the Global Fund) and for the malaria vaccine strategy budgeting\u002Fplanning process. Cost-effectiveness and equity analyses of each vaccine delivery strategy will provide evidence to help national programmes plan future malaria vaccine delivery and inform global guidance and on methods of delivering these vaccines, while providing valuable evidence on the real-world cost-effectiveness of malaria vaccination.\n\n(iii) Impact modelling will estimate the costs, impact, and cost-effectiveness of scaling up the intervention approach to the whole of Chad, under different temporal and spatial scenarios.",[30,71],"Malaria Vaccines",[73,33,74,75,76,77,78,79,80,81,82,83,84,85],"Vaccine","Implementation strategy","Children","Pediatric","synchronized","coverage","prevention","incidence","prevalence","qualitative","mixed methods","cost effectiveness","Seasonal Malaria Chemoprevention","RECRUITING","2026-04-10",{"date":89,"type":46},"2026-04-15",{"date":91,"type":46},"2025-06-16",{"date":93,"type":22},"2028-06",{"name":95,"class":53},"Epicentre",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":54},"100622856","assessing-the-feasibility-of-combining-dihydroartemisinin-piperaquine-and-primaquine-for-malaria-mass-drug-administration-in-high-endemic-communities-in-the-eastern-region-of-ghana-100622856","NCT07389057","Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Implementation Research to Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Inclusion Criteria:\n\n* must be aged 3 months and above and\n* be resident in the communities for the period of the study,\n* completed and signed a consent form from the parent or guardian of children below 18 years\n* Completed and signed assent for 12-17 years old children.\n* Completed and signed consent for those from age 18 years and above.\n\nExclusion Criteria:\n\n* Pregnant women\n* individual with a life-threatening illness (excluding malaria)\n* less than 10Kg body weight (or less than 1 year old)\n* individuals who had experienced adverse effects related to primaquine or\n* known to be G6PD deficient .","3 Months",{"count":105,"type":22},9000,[107],"NA","Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymptomatic malaria after one year. However, rapid diagnostic tests (RDTs) can miss very low-level infections, meaning some infected individuals are not treated and can continue to spread malaria.\n\nA pilot malaria mass drug administration (MDA) study using artemether-lumefantrine (AL) in the Eastern Region of Ghana showed a very large reduction (over 95%) in parasite carriage after repeated rounds of treatment. Despite this success, malaria infections later fluctuated, possibly because some parasites remained in mosquitoes and because mature gametocytes-the parasite stage responsible for transmission-are not fully eliminated by standard malaria medicines.\n\nTo better interrupt malaria transmission, this study will use MDA with dihydroartemisinin-piperaquine (DHAP) combined with a single low dose of primaquine (PQ), which targets these transmission stages. The intervention will be given to the whole community every two months (six times per year) and compared with the current standard malaria control measures.\n\nThe study will examine whether this approach reduces malaria parasite carriage, whether malaria returns after treatment stops, and whether repeated MDA affects malaria drug resistance markers in the population. This two-year implementation research will generate practical evidence to guide national malaria policy in Ghana and inform the potential use of MDA in other malaria-endemic African countries.",[110,29,30,111],"Malaria Asymptomatic Parasitaemia","Malaria Transmission",[33,113,114,115,116],"Mass drug administration","Ghana","Feasibility","Implementation Research","2026-01-30",{"date":119,"type":46},"2026-02-05",{"date":121,"type":46},"2023-11-01",{"date":123,"type":22},"2026-11-30",{"name":125,"class":53},"Noguchi Memorial Institute for Medical Research",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":17,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":54},"100583853","phase-1-experimental-malaria-infection-of-healthy-malaria-naive-adults-by-mosquito-bite-with-the-genetically-modified-plasmodium-falciparum-nf54igp3-gap-100583853","NCT06881732","Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54\u002FiGP3 GAP","iGP3-SWITCH","INCLUSION CRITERIA:\n\n* Able and willing to complete the informed consent process\n* Available for the entire planned study duration\n* Male or Female\n* Aged 18 to 55 years\n* Willing to have blood samples collected, stored indefinitely and used for research purposes\n* Willing to defer blood donations for at least six months after the EoS visit (D180)\n* Agreement to adhere to specific Lifestyle Considerations throughout study duration\n\nClinical Criteria:\n\n* Total body weight ≥ 50 kg, and a body mass index (BMI) within the range of 18 to 32 kg\u002Fm2 (inclusive)\n* In good general physical and mental health as evaluated through a comprehensive clinical assessment\n* Vital signs at screening and pre-inoculation within normal clinical range\n* Electrocardiograph (ECG) without significant abnormalities, including: QTcF ≤450 ms for males, QTcF ≤470 ms for females, PR interval ≤210 ms\n\nLaboratory Criteria:\n\n* O negative blood type\n* Haemoglobin, white cell count and platelet levels within normal laboratory ranges\n* Ferritin, creatinine and alanine aminotransferase (ALT) within normal laboratory ranges\n* No clinically significant abnormality in coagulation or clotting\n* Normal G6PD enzyme activity levels as defined by the parameters of the specific quantitative G6PD test performed at screening\n* Negative for blood borne viruses, including Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus type 1 (HTLV); and other blood borne pathogens including West Nile Virus (WNV), Babesia species, Treponema pallidum, and Trypanosoma cruzi\n\nCriteria specific to female participants:\n\n* Post-menopausal for at least 1 one year, post-hysterectomy, or bilateral oophorectomy with a correlating follicle stimulating hormone (FSH) level.\n\nOR\n\n* Females of childbearing age have a negative beta-human chorionic gonadotrophin (b-HCG) pregnancy test (urine or serum) on day of enrolment and prior to CHMI inoculation and agreement to use effective birth control through the duration of the study.\n\nEXCLUSION CRITERIA:\n\n* Participant lives alone and is unable provide contact details of a support person who is aware of the individual's participation in the study and is available to provide assistance if required\n* Participation in any investigational product study within the 12 weeks preceding inoculation\n* Positive urine drug test at screening or on the day of malaria inoculation unless there is an explanation acceptable to the Investigator (e.g. the volunteer has stated in advance that they consumed a prescription or over-the-counter product which contained the detected drug) and\u002For the volunteer has a negative urine drug screen on retest by the pathology laboratory\n* Positive alcohol breath test at screening or on the day of malaria inoculation\n\nMalaria History:\n\n* Any previous history of malaria infection, including participation in a malaria research study\n* Receipt of a malaria vaccination at any time, including as part of a research study\n* Travelled to or lived (more than two weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region over the course of the study\n* Lived for more than one year in a malaria-endemic region in the past 10 years\n* Lived in a malaria-endemic region for more than 10 years inclusive\n\nClinical History:\n\n* Anyone who is pregnant, breastfeeding or planning pregnancy during the study period\n* History of severe allergic reaction, including angioedema or anaphylaxis\n* Receipt of any live attenuated vaccines within 21 days prior to enrolment\n* Has ever received a blood transfusion\n* Use of blood products or immunoglobulins within the previous 6 months\n* Without good peripheral venous access\n* Clinical history of: Sickle cell disease, sickle cell trait or other haemoglobinopathies; Splenectomy or fuctional asplenia; Skeeter syndrome or anaphylactic response to mosquito bites\n* Known intolerance, hypersensitivity or other contraindication to artemether or other artemisinin derivatives, lumefantrine, atovaquone, proguanil, primaquine, or artesunate or any of its excipients\n* Use or planned use of any drug, including antibiotics, with antimalarial activity four weeks prior to inoculation\n* Use of any of the following drugs: Anticoagulants (within 14 days of enrolment); Systemic corticosteroids (within 3 months of enrolment); Any prescription or non-prescription drugs, and or supplements that in the opinion of the investigator would jeopardise the safety of the volunteer\n* Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, infectious diseases, psychiatric disorders, heart disease, or cancer\n\nClinical Risk:\n\n* Evidence at screening of increased cardiovascular disease risk (defined as \\>10%, 5-year risk for those greater than 35 years of age), as determined by the Australian Absolute Cardiovascular Disease Risk Calculator","18 Years","55 Years",{"count":136,"type":22},2,[25],"The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54\u002FiGP3 will safely infect humans with malaria. The investigators will also determine how the parasite grows in humans, and the effect of anti-malarial drugs.\n\nResearchers will use a controlled human malaria infection (CHMI) model to infect participants with malaria to observe the development of the disease, collect malaria-infected blood, and then treat the participants to cure the malaria infection.\n\nThe collected malaria-infected blood will be used to create a frozen stock of malaria parasites for use in future research.",[29,30,111],[141,142,143],"SWITCH","NF54\u002FiGP3","Plasmodium falciparum","2025-03-11",{"date":146,"type":46},"2025-03-18",{"date":148,"type":22},"2025-07",{"date":150,"type":22},"2026-07",{"name":152,"class":53},"University of Melbourne",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":16,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":169,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100561332","diagnostic-access-to-self-care-and-health-services-in-low-and-middle-income-countries-dash---phase-ii-100561332","NCT06588790","Diagnostic Access to Self-Care and Health Services in Low and Middle Income Countries (DASH) - Phase II","DASH","Inclusion Criteria:\n\n* Resides in the household and has spent ≥1 night at the house in the prior four weeks\n* Plans to reside in the house for duration of the study\n* Willing and able to provide informed consent, assent, or parental consent (where needed)",{"count":161,"type":22},2250,[107],"Our primary goal is to determine if on-demand, home-based rapid testing, or rapid testing done by a community health worker (CHW) results in people testing for diseases more frequently and getting care more quickly. These two testing approaches will be compared to how individuals would normally test if they were concerned about certain diseases.\n\nThe main questions the study aims to answer are:\n\n* Do either of the testing approaches result in more people testing themselves for certain diseases when needed?\n* Does self-testing at home or testing done by a community health worker increase the number of individuals receiving test results and getting care\u002Ftreatment more quickly?\n* Does at-home screening for high blood pressure and diabetes result in lower blood pressure and hemoglobin A1c levels (an indicator for diabetes)?",[30,165,166,167,168],"Pregnancy","HIV","Diabetes","Hypertension",[170,171,172,166,33,165,173,174,175,176,168,167,177],"Rapid diagnostic testing","Rapid testing","Self-testing","Home-based testing","community-based testing","Community Health Worker","Blood pressure","RDT","2024-09-07",{"date":180,"type":46},"2024-09-19",{"date":182,"type":22},"2024-10",{"date":184,"type":22},"2025-12",{"name":186,"class":53},"University of Washington",3]